CORBF vs. VMD, CRVO, CRDF, RAPT, CTMX, MCRB, ELMD, CYBN, RPTX, and PRLD
Should you be buying Global Cord Blood stock or one of its competitors? The main competitors of Global Cord Blood include Viemed Healthcare (VMD), CervoMed (CRVO), Cardiff Oncology (CRDF), RAPT Therapeutics (RAPT), CytomX Therapeutics (CTMX), Seres Therapeutics (MCRB), Electromed (ELMD), Cybin (CYBN), Repare Therapeutics (RPTX), and Prelude Therapeutics (PRLD). These companies are all part of the "medical" sector.
Viemed Healthcare (NASDAQ:VMD) and Global Cord Blood (NYSE:CORBF) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, analyst recommendations, valuation, institutional ownership, media sentiment, dividends and risk.
74.2% of Viemed Healthcare shares are held by institutional investors. 19.2% of Viemed Healthcare shares are held by company insiders. Comparatively, 0.5% of Global Cord Blood shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Viemed Healthcare has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Global Cord Blood has a beta of -0.23, suggesting that its stock price is 123% less volatile than the S&P 500.
Viemed Healthcare has a net margin of 5.32% compared to Viemed Healthcare's net margin of 0.00%. Global Cord Blood's return on equity of 9.32% beat Viemed Healthcare's return on equity.
Viemed Healthcare received 3 more outperform votes than Global Cord Blood when rated by MarketBeat users.
In the previous week, Global Cord Blood had 1 more articles in the media than Viemed Healthcare. MarketBeat recorded 5 mentions for Global Cord Blood and 4 mentions for Viemed Healthcare. Global Cord Blood's average media sentiment score of 1.68 beat Viemed Healthcare's score of 0.00 indicating that Viemed Healthcare is being referred to more favorably in the media.
Global Cord Blood has higher revenue and earnings than Viemed Healthcare.
Summary
Viemed Healthcare beats Global Cord Blood on 9 of the 12 factors compared between the two stocks.
Get Global Cord Blood News Delivered to You Automatically
Sign up to receive the latest news and ratings for CORBF and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CORBF and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
CORBF vs. The Competition
Global Cord Blood Competitors List
Related Companies and Tools
